LDL Cholesterol Rises With BMI Only in Lean Individuals: Cross-sectional U.S. and Spanish Representative Data

OBJECTIVE Elevated LDL cholesterol (LDLc) is not strongly associated with obesity or metabolic syndrome (MS), but this relationship repeatedly has been examined assuming a linear association. This study aimed to assess the dose-response relationship between body mass index (BMI) or waist circumference (WC) and LDLc and to evaluate its link to metabolic impairment. RESEARCH DESIGN AND METHODS Participants in the continuous National Health and Nutrition Examination Survey (NHANES, 1999–2010) (n = 12,383) and the Study on Nutrition and Cardiovascular Risk (ENRICA, 2008–2010) (n = 11,765), representative samples of U.S. and Spanish noninstitutionalized populations, were cross-sectionally investigated. LDLc was modeled with age- and sex-adjusted regressions, with BMI and/or WC as explanatory variables included in models as two-segment linear and natural cubic splines. RESULTS In NHANES and ENRICA, slopes of the BMI-LDLc association changed (P < 0.001) at BMI 27.1 and 26.5 kg/m2, respectively, forming an inverted U shape. Below these BMI inflection points, LDLc rose 2.30 and 2.41 mg/dL per kg/m2 (both P < 0.001). However, above said points, LDLc declined −0.37 and −0.38 mg/dL per kg/m2 (both P < 0.001). The WC-LDLc relationship was similar to the BMI-LDLc relationship. Accumulation of MS traits was associated with a weakening of the positive BMI-LDLc association among lean participants (below the BMI inflection point). Aging shifted the inflection point of the BMI-LDLc relationship to lower BMI values. CONCLUSIONS The BMI- and WC-LDLc relationships have inverted U shapes. Diminishing associations between BMI and LDLc might indicate metabolic impairment as a result of aging or other metabolic diseases. In lean individuals, small weight losses might help to lower LDLc for cardiovascular prevention.

[1]  International Association for the Study of Obesity , 2018, The Grants Register 2019.

[2]  Sara M. Willems,et al.  Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis. , 2016, JAMA.

[3]  A. Hoes,et al.  2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention , 2016, Atherosclerosis.

[4]  N. Lundbom,et al.  Kinetic and Related Determinants of Plasma Triglyceride Concentration in Abdominal Obesity: Multicenter Tracer Kinetic Study , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[5]  R. Brook,et al.  Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 × 2 factorial Mendelian randomization study. , 2015, Journal of the American College of Cardiology.

[6]  Hynek Pikhart,et al.  HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials , 2015, The Lancet.

[7]  Alex P. Reiner,et al.  Mendelian randomization of blood lipids for coronary heart disease , 2014, European heart journal.

[8]  Y. Bao,et al.  Positive Relationship between Serum Low-Density Lipoprotein Cholesterol Levels and Visceral Fat in a Chinese Nondiabetic Population , 2014, PloS one.

[9]  E. Rimm,et al.  Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1·8 million participants , 2014, The Lancet.

[10]  K. Parhofer,et al.  Diabetic dyslipidemia. , 2014, Metabolism: clinical and experimental.

[11]  Yechiam Ostchega,et al.  Health and nutrition examination survey plan and operations, 1999-2010 , 2013 .

[12]  M. Arca,et al.  Mechanisms of diabetic dyslipidemia: relevance for atherogenesis. , 2012, Current vascular pharmacology.

[13]  F. Civeira,et al.  Metabolic syndrome and coronary heart disease among Spanish male workers: a case-control study of MESYAS. , 2012, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[14]  F. Rodríguez‐Artalejo,et al.  Magnitude and Management of Hypercholesterolemia in the Adult Population of Spain, 2008-2010, The ENRICA Study , 2012 .

[15]  F. Rodríguez‐Artalejo,et al.  [Rationale and methods of the study on nutrition and cardiovascular risk in Spain (ENRICA)]. , 2011, Revista espanola de cardiologia.

[16]  P. Kolh,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, European heart journal.

[17]  K. Reynolds,et al.  Cardiovascular Disease Risk of Abdominal Obesity vs. Metabolic Abnormalities , 2011, Obesity.

[18]  Mark Woodward,et al.  Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. , 2011, Lancet.

[19]  B. Vergès Abnormal hepatic apolipoprotein B metabolism in type 2 diabetes. , 2010, Atherosclerosis.

[20]  J. Danesh,et al.  Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies , 2010, The Lancet.

[21]  L. Heinberg,et al.  Discrepancy Between Ideal and Realistic Goal Weights in Three Bariatric Procedures: Who Is Likely to Be Unrealistic? , 2010, Obesity surgery.

[22]  S. Grundy,et al.  Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As , 2009, Circulation.

[23]  R. Collins,et al.  Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies , 2009, Lancet.

[24]  R. Collins,et al.  Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies , 2009, The Lancet.

[25]  D. Corella,et al.  Metabolic syndrome pathophysiology: the role of adipose tissue. , 2008, Kidney international. Supplement.

[26]  E. Livingston,et al.  Do current body mass index criteria for obesity surgery reflect cardiovascular risk? , 2007, Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery.

[27]  S. Grundy Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance. , 2006, Clinical cornerstone.

[28]  C. Lamendola,et al.  Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. , 2004, Metabolism: clinical and experimental.

[29]  P. Ferré,et al.  Adipocyte cholesterol balance in obesity. , 2004, Biochemical Society transactions.

[30]  K. Frayn,et al.  Adipose tissue as a buffer for daily lipid flux , 2002, Diabetologia.

[31]  K. Jablonski,et al.  Effects of obesity and body fat distribution on lipids and lipoproteins in nondiabetic American Indians: The Strong Heart Study. , 2000, Obesity research.

[32]  S. Foley,et al.  Age-dependence of the relationship between adiposity and serum low density lipoprotein cholesterol in men. , 2013, Journal of the American College of Nutrition.

[33]  R. L. Berg,et al.  Determinants of serum lipid and lipoprotein concentrations in children. , 1995, Epidemiology.

[34]  S M Grundy,et al.  Excess body weight. An under-recognized contributor to dyslipidemia in white American women. , 1994, Archives of internal medicine.

[35]  S. Grundy,et al.  Excess body weight: An underrecognized contributor to high blood cholesterol levels in white American men , 1993 .

[36]  S. Grundy,et al.  Metabolic and health complications of obesity. , 1990, Disease-a-month : DM.